HIGHLIGHTS
- who: Fimasartan Ameliorates Nonalcoholic Fatty and colleagues from the Cardiovascular Center, Guro Hospital, Korea University, Guro-dong, Guro-gu, Seoul, Republic of Korea have published the paper: Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPAR 𝛿 Regulation in Hyperlipidemic and Hypertensive Conditions, in the Journal: PPAR Research of 13/03/2017
- what: In this study, to investigate the potential of fimasartan in NAFLD treatment in hyperlipidemic and hypertensive conditions, the expression levels of various biomarkers related to fatty_acid metabolism were determined in HepG2 and differentiated 3T3-L1 cells and liver and visceral fat tissues harvested from . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.